Earnings call transcript: Albertsons Q1 2025 sees steady EPS, stock dips

Albertsons Companies (ACI) reported Q1 2025 adjusted EPS of $0.55, meeting consensus, and revenue of $24.88 billion, slightly exceeding forecasts. Despite the revenue beat, the stock declined 2.39% pre-market. Key drivers included robust 25% e-commerce growth and 20% pharmacy sales, the latter partially fueled by GLP-1 medications, though gross margin compressed 85 basis points due to strategic price investments and a shift towards lower-margin digital and pharmacy channels. The company raised its FY2025 identical sales growth outlook to 2.0%-2.75% but maintained EBITDA and EPS guidance, signaling continued investment in customer value, digital expansion, and productivity initiatives to drive unit growth and long-term engagement, with benefits anticipated in the second half of the fiscal year.

Analysis

Albertsons Companies' Q1 2025 results present a clear strategic trade-off, with revenue of $24.88 billion exceeding forecasts while adjusted EPS of $0.55 only met expectations, leading to a 2.39% pre-market stock decline. The top-line outperformance was propelled by high-growth, lower-margin channels, specifically a 25% increase in e-commerce sales and a 20% rise in pharmacy revenue, with GLP-1 medications contributing to half of the pharmacy sales composition. This mix shift, coupled with deliberate price investments aimed at driving grocery unit sales, resulted in an 85-basis-point compression in the gross margin rate to 27.1% and a decline in adjusted EBITDA to $1.11 billion. Tellingly, management raised its full-year identical sales growth guidance to 2.0%-2.75% but maintained its EBITDA and EPS outlook, signaling that the incremental revenue is not expected to flow to the bottom line in the near term. This reinforces the narrative that fiscal 2025 is an investment year, where the company is sacrificing immediate profitability to fund its "Customers for Life" strategy, modernize technology, and execute a $1.5 billion productivity plan intended to fuel a return to its long-term growth algorithm in fiscal 2026.

Key Decisions for Investors

• Investors should weigh the current margin compression against the potential long-term benefits of strategic investments in digital, pharmacy, and price, with a key catalyst being the promised sequential improvement in core grocery unit volumes in the second half of FY2025.
• Given that the raised sales guidance did not translate to a higher profit forecast, it is crucial to monitor gross margin trends and the execution of productivity initiatives, as their success is critical to offsetting wage inflation and funding the growth strategy.
• For value-oriented investors, the stock's defensive characteristics, including a 2.71% dividend yield, significant share repurchases, and a valuation described as near fair value, could offer an attractive profile, assuming a tolerance for the multi-year investment horizon.